Skip Navigation LinksHome > June 2011 - Volume 18 - Issue 6 > Vasomotor symptoms and cardiovascular events in postmenopaus...
Menopause:
doi: 10.1097/gme.0b013e3182014849
Original Articles

Vasomotor symptoms and cardiovascular events in postmenopausal women

Szmuilowicz, Emily D. MD, MS1; Manson, JoAnn E. MD, DrPH2; Rossouw, Jacques E. MBChB, MD3; Howard, Barbara V. PhD4; Margolis, Karen L. MD, MPH5; Greep, Nancy C. MD6; Brzyski, Robert G. PhD, MD7; Stefanick, Marcia L. PhD8; O'Sullivan, Mary Jo MD9; Wu, Chunyuan MS10; Allison, Matthew MD, MPH11; Grobbee, Diederick E. MD, PhD12; Johnson, Karen C. MD, MPH13; Ockene, Judith K. PhD14; Rodriguez, Beatriz L. MD, MPH, PhD15; Sarto, Gloria E. MD, PhD16; Vitolins, Mara Z. DrPH17; Seely, Ellen W. MD18

Collapse Box

Abstract

Objective: Emerging evidence suggests that women with menopausal vasomotor symptoms (VMS) have increased cardiovascular disease (CVD) risk as measured by surrogate markers. We investigated the relationships between VMS and clinical CVD events and all-cause mortality in the Women's Health Initiative Observational Study (WHI-OS).

Methods: We compared the risk of incident CVD events and all-cause mortality between four groups of women (total N = 60,027): (1) no VMS at menopause onset and no VMS at WHI-OS enrollment (no VMS [referent group]), (2) VMS at menopause onset but not at WHI-OS enrollment (early VMS), (3) VMS at both menopause onset and WHI-OS enrollment (persistent VMS [early and late]), and (4) VMS at WHI-OS enrollment but not at menopause onset (late VMS).

Results: For women with early VMS (n = 24,753), compared with no VMS (n = 18,799), hazard ratios (95% CIs) in fully adjusted models were as follows: major coronary heart disease (CHD), 0.94 (0.84-1.06); stroke, 0.83 (0.72-0.96); total CVD, 0.89 (0.81-0.97); and all-cause mortality, 0.92 (0.85-0.99). For women with persistent VMS (n = 15,084), there was no significant association with clinical events. For women with late VMS (n = 1,391), compared with no VMS, hazard ratios (95% CIs) were as follows: major CHD, 1.32 (1.01-1.71); stroke, 1.14 (0.82-1.59); total CVD, 1.23 (1.00-1.52); and all-cause mortality, 1.29 (1.08-1.54).

Conclusions: Early VMS were not associated with increased CVD risk. Rather, early VMS were associated with decreased risk of stroke, total CVD events, and all-cause mortality. Late VMS were associated with increased CHD risk and all-cause mortality. The predictive value of VMS for clinical CVD events may vary with the onset of VMS at different stages of menopause. Further research examining the mechanisms underlying these associations is needed. Future studies will also be necessary to investigate whether VMS that develop for the first time in the later postmenopausal years represent a pathophysiologic process distinct from the classic perimenopausal VMS.

©2011The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.